Deapril-ST en es it fr

Deapril-ST Brand names, Deapril-ST Analogs

Deapril-ST Brand Names Mixture

  • No information avaliable

Deapril-ST Chemical_Formula


Deapril-ST RX_link

No information avaliable

Deapril-ST fda sheet

Deapril-ST msds (material safety sheet)

Deapril-ST Synthesis Reference

No information avaliable

Deapril-ST Molecular Weight

591.741 g/mol

Deapril-ST Melting Point

No information avaliable

Deapril-ST H2O Solubility

No information avaliable

Deapril-ST State


Deapril-ST LogP


Deapril-ST Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Deapril-ST Indication

For use as an adjunct therapy for patients with dementia

Deapril-ST Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Deapril-ST Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Deapril-ST side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Deapril-ST Patient Information

No information avaliable

Deapril-ST Organisms Affected

Humans and other mammals